

**EXHIBIT G**

Mark Reisenauer

December 8, 2005

New York, NY

1

1 IN THE UNITED STATES DISTRICT COURT

2 FOR THE DISTRICT OF MASSACHUSETTS

3 CASE NO.

4 -----\*

5 )

6 IN RE: PHARMACEUTICAL INDUSTRY )

7 AWP LITIGATION )

8 )

9 -----\*

10

11 Thursday, December 8, 2005

12 New York, New York

13 Time: 9:35 a.m.

14

15 Videotaped Deposition of MARK REISENAUER,

16 taken by Plaintiffs, at the offices of David Polk &

17 Wardwell, 450 Lexington Avenue, New York, New York,

18 on Thursday, December 8, 2005, pursuant to Notice,

19 as taken by and before Josephine H. Fassett, a

20 Certified Shorthand Reporter and Notary Public of

21 the State of New York.

**CERTIFIED COPY**

HENDERSON LEGAL SERVICES  
202-220-4158

Mark Reisenauer

December 8, 2005

New York, NY

78

1 of free samples to sales representatives. Did Zeneca  
2 relabel free samples that had been given to sales  
3 representatives for retail sale?

4 A. Not to my knowledge, no.

5 Q. You just made prospective changes --

6 A. That's correct.

7 Q. -- to allocations to take that into  
8 consideration?

9 At that time did you have any supervisory  
10 responsibility over sales representatives with  
11 respect to their distribution of free samples?

12 A. No.

13 Q. Do you know who did?

14 A. The district manager would.

15 Q. Anyone else?

16 A. And then the subsequent chain of command in  
17 sales management.

18 Q. Are you familiar with the rules that exist  
19 that Zeneca had at that time with respect to the  
20 distribution of free samples?

21 A. Not specifically other than I know the one  
22 general rule, I mean that was echoed by both the

HENDERSON LEGAL SERVICES  
202-220-4158

Mark Reisenauer

December 8, 2005

New York, NY

79

1     Sales Management Department, as was the Marketing  
2     Department, was that these were for sample use only  
3     and not to be used, you know, not to be billed, you  
4     know, as retail products by the physician.

5           Q.    We had talked a little bit earlier about  
6     your understanding of the method by which physicians  
7     are reimbursed for administering Zoladex, right?

8           A.    Yes.

9           Q.    Did Zeneca -- why was reimbursement an  
10    issue that you were concerned about in connection  
11    with your roles in marketing Zoladex?

12          A.    Two perspectives or two reasons why:

13           One.   If there were problems on the part of  
14    the customer in just obtaining reimbursement, that is  
15    an impediment that, you know, an impediment to the  
16    use of the drug obviously; and much like across the  
17    entire industry, you know, we provided help and a  
18    hotline, et cetera, for billing and coding questions  
19    that may arise.   So that would be one reason why.

20           The other reason why is, as I had mentioned  
21    earlier, the market that we were competing in was  
22    driven by, almost exclusively by that dynamic, that